Head of Compound Valuation

Aisha was awarded her PhD in Molecular Microbiology from Imperial College London where she worked to identify novel virulence regulators and druggable targets in Methicillin resistant Staphylococcus aureus. Aisha’s experience has focussed on antimicrobial resistance and the discovery of novel and alternative therapeutics to treat bacterial infections; including bacteriophage proteins, the repurposing of existing chemicals and exploiting resistance as a therapeutic target.  Prior to joining Bactobio, Aisha worked within the Infectious Disease and Vaccine Team at Kymab Ltd. leading the discovery of monoclonal antibody-based therapeutics for global priority pathogens.


At Bactobio Aisha supports the screening and evaluation of novel compounds for activity against clinically relevant bacterial species.


In her free time, Aisha enjoys travelling, eating and exercising her creative muscles – knitting, embroidering or making somewhat misshapen pottery.